Baring Private Equity Asia completed a $100m investment in Hutchison China MediTech.

Baring Private Equity Asia, a private equity firm, completed a $100m investment in Hutchison China MediTech, a biopharmaceutical company. “With this strategic investment, BPEA is demonstrating our long-term commitment to HUTCHMED, an emerging biopharma leader in Asia. The healthcare sector in China is a core area of investment focus for BPEA. HUTCHMED is developing and delivering highly differentiated oncology therapies to patients around the world and we look forward to working with the CEO and management team to support the company’s innovation and global growth aspirations," Jean Eric Salata, BPEA CEO and Founding Partner.